Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study

References

Papers of special note have been highlighted as:• of interest

• American Psychiatric Association. Diagnosis and statistical manual of mental disorders (version IV). Washington (DC): American Psychiatric Publishing; 2000.
   Google Scholar
• Bloom B, Jones LI, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat. 2013;10(258). Available from: http://www.cdc.gov/nchs/data/series/sr_10/sr10_258.pdf
   Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiat. 2006;163:716–723.
   PubMed Web of Science ®Google Scholar
• Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Brit J Psychiat. 2007;190:402–409.
   PubMed Web of Science ®Google Scholar
• Jensen PS. Fact versus fancy concerning the multimodal treatment for attention-deficit hyperactivity disorder. Can J Psychiat. 1999;44:975–980.
   PubMed Web of Science ®Google Scholar
• Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev. 2007;17:61–72.
   PubMed Web of Science ®Google Scholar
• Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res. 2009;9:95.
   PubMed Web of Science ®Google Scholar
• Molife C, Bernauer MJ, Farr AM, et al. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. Postgrad Med. 2012;124:7–22.
   PubMed Web of Science ®Google Scholar

• This article describes results from a claims database examining the prevalence and predictors of combination therapy for the treatment of ADHD in Medicaid and commercially insured populations.

• Jureidini J, Tonkin A, Jureidini E. Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs. Pediatr Drugs. 2013;15:377–391.
   PubMed Web of Science ®Google Scholar

• This article demonstrates the lack of empirical data to support or oppose polypharmacy in psychiatric disorders, including ADHD, and suggests a conservative approach until further research can be carried out.

• Treuer T, Ss G, Mendez L, et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adol Psychop. 2013;23:179–193.
   PubMed Web of Science ®Google Scholar

• This literature review article suggests that drug combination may benefit some, but not all, patients who have tried several ADHD medications without success.

• Pliszka SR. The Texas children’s medication project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Psy. 2006;45:642–657.
   Google Scholar
• Brown TE. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adol Psychop. 2004;14:129–136.
   PubMed Web of Science ®Google Scholar
• Adler L, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8:409–415.
   PubMedGoogle Scholar
• Wilens TE, Hammerness P, Utzinger L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I effectiveness. J Child Adol Psychop. 2009;19:485–492.
   PubMed Web of Science ®Google Scholar
• Carlson GA, Dunn D, Kelsey D, et al. A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2007;1:10.
   PubMedGoogle Scholar
• Hammerness P, Georgiopoulos A, Doyle RL, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II tolerability and pharmacokinetics. J Child Adol Psychop. 2009;19:493–499.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Pscyhopharmacology Research Branch, Division of Extramural Research Programs; 1976.
   Google Scholar
• Connor C, Erhardt D, Sparrow E. Conners’ adult ADHD rating scales. Tonawanda (NY): Multi-Health Systems Inc; 1999.
   Google Scholar
• Barkley R. Attention deficit hyperactivity disorder: a clinical handbook. 3rd ed. New York (NY): Guildford Press; 2006.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.
   Google Scholar
• Austin PC, Mamdani MM, Stukel TA, et al. The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med. 2005;24:1563–1578.
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Savill N. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol. 2013;28:204–211.
   PubMed Web of Science ®Google Scholar

• This comprehensive review article demonstrates how incremental response time to atomoxetine should be considered when comparing treatment options, noting how atomoxetine requires at least 12 weeks for full response to be demonstrated in children/adolescents.

• Young JL, Sarkis E, Qiao M, et al. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo controlled trial. Clin Neuropharmacol. 2011;34:51–60.
   PubMed Web of Science ®Google Scholar
• Jaworowski S, Benarroch F, Gross-Tsur V. Concomitant use of atomoxetine and OROS®-methylphenidate in a 10-year old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. J Child Adol Psychop. 2006;16:365–370.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Sitholey P. Combination of atomoxetine and methylphenidate in attention deficit/hyperactivity disorder: a case report. J Can Acad Child Adol Psychiatr. 2008;17:3.
   Google Scholar
• Niederhofer H. Atomoxetine may improve methylphenidates’ efficacy in treatment of ADHD? Psychiat Danub. 2009;21:330.
   PubMed Web of Science ®Google Scholar
• Clemow DB. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients. Postgrad Med. 2014;126:196–198.
   PubMed Web of Science ®Google Scholar

• This article provides commentary on the frequent underdosing of atomoxetine for the treatment of ADHD and how this underdosing may be associated with poor patient outcomes.

• Lawson KA, Johnsrud M, Hodgkins P, et al. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther. 2012;34:944–956.
   PubMed Web of Science ®Google Scholar
• Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115:e749–e757.
   PubMed Web of Science ®Google Scholar
• Morris DW, Toups M, Trivedi MH. Measurement-based care in the treatment of clinical depression. Focus. 2012;10:428–433.
   Google Scholar
• Kelly RP, Yeo KP, Teng CH. et al. Hemodynamic effects of acute administration of atomoxetine and methylphenidate. J Clin Pharmacol. 2005;45:851–855.
   PubMed Web of Science ®Google Scholar

• This article describes the results of atomoxetine combination therapy with methylphenidate in regard to cardiovascular effects, showing there was no synergistic increase in heart rate or cardiovascular risk.

• Sofuoglu M, Poling J, Hill K, et al. Atomoxetine attenuates dextroamphetamine effects in humans. Am J Drug Alcohol Ab. 2009;35:412–416.
   PubMed Web of Science ®Google Scholar